Search | Clinical Trials Finder

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC); Drug · Other
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Maimi, Florida

Conditions: Lupus Nephritis (LN)
Interventions: Atacicept, Placebo; Drug
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 26
States / cities: Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more

Conditions: Degenerative Disc Disease
Interventions: Active Allograft, Placebo; Other
Lead sponsor: VIVEX Biologics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 218 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: Santa Monica, California • Walnut Creek, California • Tampa, Florida + 10 more

Conditions: Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions: Efprezimod alfa, Methotrexate, Tacrolimus, Placebo; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Romiplostim, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more

Conditions: Pulmonary Embolism, Deep Vein Thrombosis
Interventions: SR34006 (idraparinux sodium) Injection; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 32
States / cities: Bay Pines, Florida • Brandon, Florida • Jacksonville, Florida + 23 more

Conditions: Alzheimers Disease
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 55 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Sun City, Arizona • Delray Beach, Florida

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: TX000045- Dose A, TX000045- Dose B, Placebo; Drug
Lead sponsor: Tectonic Therapeutic; Industry
Eligibility: 18 Years to 83 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more

Conditions: Arthritis, Rheumatoid
Interventions: Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri

Conditions: Hyperparathyroidism, Secondary
Interventions: Placebo, Etelcalcetide; Drug
Lead sponsor: KAI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Cypress, California • Shreveport, Louisiana • Houston, Texas

Conditions: Migraine Prophylaxis
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more

Conditions: HIV Infections
Interventions: HIV-1 gag DNA, IL-15 DNA adjuvant, IL-12 DNA adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2008
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 2 more

Conditions: Sensorineural Hearing Loss
Interventions: FX-322, Placebo; Drug
Lead sponsor: Frequency Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congestive Heart Failure
Interventions: D-ribose, Placebo; Drug · Other
Lead sponsor: RiboCor, Inc.; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 20
States / cities: Long Beach, California • Modesto, California • Sylmar, California + 17 more

Conditions: Osteoarthritis of the Knee
Interventions: Bone morphogenetic protein 7; Drug
Lead sponsor: Stryker Biotech; Industry
Eligibility: 40 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Gainesville, Florida • Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: Fresno, California • Los Angeles, California • Montclair, California + 10 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 27
States / cities: Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more

Conditions: Lumbar Puncture, Topical Analgesia
Interventions: J-Tip, EMLA, Lidocaine; Device · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 18 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: TUTI-16 (1.0 mg), Placebo; Biological · Other
Lead sponsor: Thymon, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo; Drug
Lead sponsor: Tibotec BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more

Conditions: Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus, AIDS
Interventions: Vivitrol- Intramuscular naltrexone (depot-formulation), Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Venous Stasis Ulcer, Venous Leg Ulcer
Interventions: MTX-001 (human amniotic fluid); Biological
Lead sponsor: Merakris Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Tucson, Arizona • Castro Valley, California • Los Angeles, California + 8 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis
Interventions: Pre-filled Auto-injector Containing Placebo; Device
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Miami, Florida • Duncansville, Pennsylvania

Search by objective public record fields.

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults

FX-322 in Sensorineural Hearing Loss

Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction

Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Tezepelumab COPD Exacerbation Study

Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children

Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Alcohol Pharmacotherapy for HIV+ Prisoners

MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector